SiBionics and PharmaSens Explore New Horizons in Automated Insulin Delivery
SiBionics and PharmaSens presented advancements in diabetes care at the EASD meeting. The goal is to develop automated insulin delivery.
SiBionics, a company focused on diabetes care, presented its "See More, Act Earlier" concept at the 2026 European Association for the Study of Diabetes (EASD) meeting in Milan. This vision aims to link continuous glucose monitoring with the future of diabetes management, seeking to improve patient outcomes through automated insulin delivery.
The company also indicated a collaboration with PharmaSens, although specific details were not disclosed. The apparent shared objective is to develop more advanced solutions that significantly automate insulin delivery. This could involve creating new devices or systems that integrate with existing insulin pumps or offer entirely new methods for blood sugar management.
The advancement of automated insulin delivery represents a significant step forward in diabetes care. It has the potential to reduce the daily burden on patients, improve glucose control, and consequently help prevent long-term diabetes complications. The EASD meeting provides a venue for leading researchers and companies to showcase the latest findings and technologies.
SiBionics' "See More, Act Earlier" vision emphasizes the importance of proactive care. Continuous monitoring allows for quicker responses to blood glucose fluctuations, which is critical for preventing hypo- and hyperglycemia. The potential collaboration with PharmaSens could accelerate the translation of these principles into practical applications.